石四藥(02005.HK)大輸液銷售目標保持為16億
石四藥(02005.HK)執行董事王憲軍於記者會指,公司大部份藥物都列入國家名冊中,而今年新增一隻阿比多爾膠囊被納入國家2019版醫保目錄,相信整體正面。
他指,保持大輸液16億的銷售目標,上半年已售7.8億,相信下半年銷售會較上半年多,有信心全年可達標。他指現時有關市場已由400多家下降至10多間,而首5間已佔市場份額80-90%。
至於出口方面,他指上半年銷量增13%,與銷售增速一致,長遠希望保持在佔銷售比例10%。
他表示,公司會繼續堅持「仿創結合」的新產品開發,以注射劑為基礎,下半年有望取得6項注射劑和口服製劑生產批件,並會提升安瓿產品的產能,而河北廣祥製藥一期原料藥項目已竣工及投入試生產,預期月內進行GMP認證現場檢查。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.